SV

Street Verdict

Analyst Scorecard

A record of what Bajaj Broking Analysis said publicly, with the source. Not advice.

“Bullish on Piramal Pharma, recommending a buying range of ₹193-203 with a 12-month target price of ₹229, indicating close to 16% upside. The stock is forming a base around its long-term 52-week EMA post-correction, providing a fresh entry opportunity with a favorable risk-reward setup. Biotech funding in the USA is improving, and its inhalation anaesthesia business is seeing demand uptick.”

Bajaj Broking Analysis’s track record (trackable calls only): 6 graded calls · 95% CI 61–100%

Piramal Pharma LtdBullishCalled 14 Mar 2025
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

Entry zone: ₹193–₹203. The call starts at the first close that comes into it.

Target ₹229, as stated.

Window: 12 months, the time frame the call states ("12-month").

Waiting for a close to reach the entry zone.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Piramal Pharma Ltd since this call

1-year tracking window
Read the original articleSee Bajaj Broking Analysis’s full track record